Entrada Therapeutics
Stock Forecast, Prediction & Price Target
Entrada Therapeutics (TRDA) stock Price Target by analysts
$20
Potential upside: 263.63%
Entrada Therapeutics price prediction
What is Entrada Therapeutics stock analysts` prediction?
Entrada Therapeutics stock forecast: Based on 1 Wall Street analysts` predicted price targets for Entrada Therapeutics in the last 3 months, the avarage price target is $20, with a high forecast of $NaN. The average price target represents a 263.63% change from the last price of $5.5.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Entrada Therapeutics stock Price Target by analysts
Full breakdown of analysts given Entrada Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Boobalan Pachaiyappan H.C. Wainwright | 0% 0/1 | 11 months ago | $20 263.63% upside | $18.03 | StreetInsider | Previous targets (0) |
Raghuram Selvaraju H.C. Wainwright | 0% 0/1 | over 1 year ago | $18 227.27% upside | $14.24 | TheFly | Previous targets (0) |
Entrada Therapeutics Financial Estimates
Entrada Therapeutics Revenue Estimates
Entrada Therapeutics EBITDA Estimates
Entrada Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $129.01M 0% | Avg: $45.68M Low: $36.66M High: $57.29M avg. -64.59% | Avg: $45.10M Low: $40.92M High: $51.24M avg. -1.25% | Avg: $174.21M Low: $158.06M High: $197.92M avg. 286.24% | Avg: $304.76M Low: $276.51M High: $346.24M avg. 74.93% |
Net Income
% change YoY
| $-50.07M N/A | $-87.45M -74.66% | $-6.68M 92.35% | Avg: $-138.08M Low: $-142.11M High: $-73.04M avg. -1965.60% | Avg: $-158.58M Low: $-145.42M High: $-92.87M avg. -14.84% | Avg: $-144.42M Low: $-169.98M High: $-127.02M avg. 8.92% | Avg: $21.64M Low: $19.03M High: $25.47M avg. 114.98% |
EBITDA
% change YoY
| $-51.12M N/A | $-97.24M -90.20% | $-321K 99.66% | Avg: $36.52M Low: $29.31M High: $45.80M avg. 11477.34% | Avg: $36.06M Low: $32.71M High: $40.96M avg. -1.25% | Avg: $139.28M Low: $126.37M High: $158.24M avg. 286.24% | Avg: $243.66M Low: $221.07M High: $276.82M avg. 74.93% |
EPS
% change YoY
| -$1.6 N/A | -$2.79 -74.37% | -$0.2 92.83% | Avg: -$3.48 Low: -$4.3 High: -$2.21 avg. -1641.24% | Avg: -$3.63 Low: -$4.4 High: -$2.81 avg. -4.13% | Avg: -$4.37 Low: -$5.14 High: -$3.84 avg. -20.49% | Avg: $0.66 Low: $0.58 High: $0.77 avg. 114.98% |
Operating Expenses
% change YoY
| $51.12M N/A | $97.24M 90.20% | $132.17M 35.91% | Avg: $38.83M Low: $31.16M High: $48.70M avg. -70.62% | Avg: $38.34M Low: $34.78M High: $43.56M avg. -1.25% | Avg: $148.09M Low: $134.36M High: $168.25M avg. 286.24% | Avg: $259.07M Low: $235.05M High: $294.32M avg. 74.93% |
FAQ
What is Entrada Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -464.13% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -142.11M, average is -138.08M and high is -73.04M.
What is Entrada Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 73.83% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $36.66M, average is $45.68M and high is $57.29M.
What is Entrada Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -387.72% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$4.3, average is -$3.48 and high is $-2.21.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Entrada Therapeutics stock. The most successful analyst is Boobalan Pachaiyappan.